A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.
Epistemonikos ID: 7f46b99b89d1c9f843512f7555c69f91a282068d
First added on: Mar 24, 2026